Skip to navigation menu Skip to content
High Priority Alert

We are experiencing extremely high demand in our Emergency Department. Learn more.

High Priority Alert

Masking and Visitation Changes: Due to high rates of respiratory illnesses in our community, we’ve made changes to our masking and visitation guidelines. Learn more.

Bispecific CAR T cells for Solid Tumors

Novel therapeutic-expressing dual CARs for improved CAR T-cell therapy in solid tumors

Download summary

Technology overview

Adoptive T cell-based immunotherapies have been successful in hematologic malignancies but remain challenging in solid tumors. One of the drawbacks associated with CAR T-cell therapy in solid tumors is poor engraftment and expansion of CAR T cells at tumor sites. To augment CAR T-cell therapy in solid tumors, Dr. Michael Jensen has developed bispecific CAR T cells that co-express a B cell targeting “driver CAR” and a solid tumor antigen targeting “passenger CAR.” The driver CAR promotes activation and expansion of the T cells harboring the CARs, while the passenger CAR confers tumor-targeting specificity. In vivo studies have demonstrated that bispecific CAR T cells prolong tumor suppression and extend overall animal survival. Additionally, the bispecific CAR T cells are regulatable via genetic tags engineered into the CAR constructs, allowing for periods when CAR T cells are “on” and “off.” Bispecific CAR T cells are currently in phase I clinical trials. Bispecific CAR T cells constitute a novel therapeutic approach for targeting solid tumors.


  • CAR T cell therapy for solid tumors


  • Enhanced expansion and activation of CAR T cells
  • Regulatable CAR expression

Market overview

Solid tumors account for more than 80% of cancers. About 1.7 million new cancer cases are estimated in 2019. There are over 20 active clinical trials investigating CAR T-cell therapy in solid tumors. There are no approved CAR T-cell therapies targeting solid tumors in the market.


Exclusive license

Technology type


Cell therapy

Technology status

Clinical (in phase 1 trials)

Patent status

National stage filings based on WO 2017/027291A1


Michael Jensen, MD

Learn more

To learn more about this technology, please email Kamya Rajaram.

By clicking “Accept All Cookies,” you agree to the storing of cookies on your device to enhance site navigation, analyze site usage and assist in marketing efforts. For more information, see Website Privacy.

Accept All Cookies